ALLOS THERAPEUTICS ANNOUNCES WITHDRAWAL OF EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR REVAPROXYN

Allos Therapeutics, Inc. (Nasdaq: ALTH -- News) today announced that it has withdrawn its European Marketing Authorization Application (MAA) for its investigational radiation sensitizer REVAPROXYN(TM) (efaproxiral, EFAPROXYN(TM) in the United States) for use as an adjunct to whole brain radiation therapy (WBRT) for the treatment of patients with brain metastases originating from breast cancer. The Company made this decision as a result of the Rapporteurs' Day 180 Joint Assessment Report, which concluded that the current data package was not sufficient to support approval.

Yahoo News (http://biz.yahoo.com/prnews/051011/latu081.html?.v=27)